Search
Esmolol
go.drugbank.com/drugs/DB00187ApprovedInvestigationalWithdrawnIt works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions.
Products: Esmolol Hydrochloride in Water, Esmolol Hydrochloride In Sodium ChlorideTocilizumab
go.drugbank.com/drugs/DB06273ApprovedInvestigational[L12789] It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. … [L12789] It was later approved by Health Canada on 30 April 2010.
Products: ACTEMRA (162 MG SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE), ACTEMRA 162MG/0.9ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGEDrotaverine
go.drugbank.com/drugs/DB06751ApprovedWithdrawnDrotaverine is an antispasmodic drug that works by inhibiting phosphodiesterase-4 (PDE4). … It is approved for use in Thailand as oral tablets or intramuscular injections.[L22689]
Silanol
go.drugbank.com/drugs/DB11343ApprovedSilanol is an FDA-approved food contact substance that is commonly used in organosilicon chemistry and silicate mineralogy.
Alclometasone
go.drugbank.com/drugs/DB00240ApprovedAlclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent.
C326
go.drugbank.com/drugs/DB06017ExperimentalC326 is an investigational compound under investigation in clinical trial NCT00353756 (Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease) for the treatment … The drug is composed of an IL-6–binding trimer and a IgG-binding domain.
Florquinitau (18F)
go.drugbank.com/drugs/DB19215Approvedon PET images. … [L64052,L64053] It is the second fluorine-18 tau PET imaging agent approved in the United States, after flortaucipir (Tauvid), which was approved in 2020.[L64054,L14114]
Artemisia vulgaris root
go.drugbank.com/drugs/DB14170ApprovedArtemisia vulgaris root allergenic extract is used in allergenic testing.
TTP889
go.drugbank.com/drugs/DB05131InvestigationalTTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. … TTP889 has proven to be effective in preventing clot formation in several animal models of human disease, without any signs of the bleeding associated with traditional anticoagulants.
Cystine
go.drugbank.com/drugs/DB00138ApprovedInvestigationalNutraceuticalWithdrawnA covalently linked dimeric nonessential amino acid formed by the oxidation of cysteine. Two molecules of cysteine are joined together by a disulfide bridge to form cystine.